SummaryTyrosine peptides, such as L-alanyl-L-tyrosine, have excellent solubility and are potential sources of iv tyrosine. Infusion of Lalanyl-1.-U-'T-tyrosine as part of a total parenteral nutrition reginien in the rat at a level of 0.5 mmole/kg/day resulted in rapid labeling of tissue tyrosine pools, production of I4CO2, incorporation of 14C-labeled tyrosine into protein, and minimal urinary losses (7.7%). Plasnla tyrosine levels, however, remained at fasting. Infusion of I.-alanyl-L-tyrosine at 2 mmole/kg/day increased plasnia tyrosine above fasting levels and maintained tissue tyrosine at levels seen in orally fed control animals without increasing the percent lost in urine (5.5'10). Rapid utilization of L-alanyl-L-tyrosine was noted at both infusion levels with no accumulation of peptide noted in plasma. Plasma and tissue free tyrosine pools were rapidly labeled, as was tissue protein. Radioactivity incorporated in tissue protein was shown to be tyrosine after acid hyrolysis.
SpeculationTyrosine content of parenteral solutions is limited by poor tyrosine solubility. Tyrosine peptides are soluble and are well utilized during iv feeding of adult rats. This suggests that tyrosine peptides are a reasonable source for supplying the tyrosine requirements of iv fed infants.Cystine and tyrosine are essential amino acids for some premature infants (19,33,41). Both amino acids have limited solubility, and cannot be added to total parenteral nutrition solutions in quantities sufficient to meet the infants requirements. The absence of these amino acids results in depresed cystine and tyrosine levels in infants infused with such solutions (30,35,38).Soluble peptides of cystine and tyrosine are potential sources for adding these amino acids to parenteral solutions (36). Although some studies suggested that peptide nitrogen is not well utilized during parenteral nutrition (7-1 1, 13, 16, 21, 23). peptide utilization is nearly equal to that of infused amino acids once products of the Maillard reaction are eliminated from the parenteral solutions (I I. 36, 39). Preliminary studies (36) indicated good utilization of L-alanyl-I.-tyrosine as a tyrosine source in adult rats when administered at 0.5 mmole/kg/day either by ip injection or as part of a total parenteral nutrition regimen. The peptide was utilized as a tyrosine source for protein synthesis, as evidenced by incorporation of tyrosine into tissue protein, and for energy production, as evidenced by rapid conversion to carbon dioxide. However, plasma tyrosine levels remained in the fasting range and 7.7% of peptide tyrosine was lost in the urine. The present study compares infusion of I--alanyl-L-tyrosine at 0.5 and 2.0 mmole/kg/day as part of a parenteral nutrition regimen in adult rats to determine whether: I) good utilization occurs at higher peptide infusion levels; 2) plasma tyrosine levels can be increased above fasting levels; and 3) urinary losses of tyrosine will increase at higher infusion levels.
MATERIALS AND METIIODSI.-Alanyl-L-tyrosine and L-alanyl-L-U-14C-...